Avacta opens phase 1 trial for conjugate's efficacy regarding tumours
(Alliance News) - Avacta Group PLC on Monday announced the opening of a phase 1 trial for AVA6103, a peptide-drug conjugate. Read More
| Price | 68.50p on 20-03-2026 at 19:40:05 |
|---|---|
| Change | 3.00p 4.55% |
| Buy | 70.00p |
| Sell | 67.00p |
| Last Trade: | Buy 9,000.00 at 69.00p |
| Day's Volume: | 856,931 |
| Last Close: | 69.00p |
| Open: | 66.00p |
| ISIN: | GB00BYYW9G87 |
| Day's Range | 69.00p - 69.00p |
| 52wk Range: | 27.25p - 83.20p |
| Market Capitalisation: | £301.97m |
| VWAP: | 67.53877p |
| Shares in Issue: | 437.63m |
Sector: Medicine and Biotech
Listed In: FTSE AIM All-Share,
Avacta Group (AVCT) Latest Trades |
||||
| Buy/Sell | Volume | Trade Prc | Trade Type | Trade Time |
|---|---|---|---|---|
| Buy* | 9,000 | 69.00p | Suspected BUY Trade |
16:35:06 - 20-Mar-26 |
| Buy* | 19,628 | 68.75p | Ordinary |
16:19:11 - 20-Mar-26 |
| Sell* | 25,000 | 67.6666p | Ordinary |
16:13:26 - 20-Mar-26 |
| Sell* | 24,461 | 68.45p | Ordinary |
16:11:18 - 20-Mar-26 |
| Buy* | 9,806 | 69.00p | Ordinary |
16:09:31 - 20-Mar-26 |
| Sell* | 607 | 68.05p | Ordinary |
16:08:54 - 20-Mar-26 |
| Buy* | 355 | 69.3965p | Ordinary |
16:08:54 - 20-Mar-26 |
| Buy* | 9,806 | 69.00p | Suspected BUY Trade |
16:06:33 - 20-Mar-26 |
| Buy* | 43,215 | 69.40p | Ordinary |
16:03:51 - 20-Mar-26 |
| Buy* | 36 | 69.3965p | Ordinary |
16:02:46 - 20-Mar-26 |
Avacta Group (AVCT) Regulatory News |
||
| Date | Source | Headline |
|---|---|---|
| 17th Mar 2026 7:00 am | RNS-R | Presentations of pre|CISION® Platform Candidates |
| 17th Mar 2026 7:00 am | RNS-R | Presentations of pre|CISION® Platform Candidates |
| 16th Mar 2026 7:00 am | RNS | Phase 1 study opening for AVA6103 |
| 16th Mar 2026 7:00 am | RNS | Phase 1 study opening for AVA6103 |
| 24th Feb 2026 7:00 am | RNS | PreCISION payload delivery advantage over ADC |
| 18th Feb 2026 7:00 am | RNS-R | Avacta to Participate in Conference March 2026 |
| 9th Feb 2026 7:00 am | RNS | Appointment of CSO |
| 3rd Feb 2026 7:00 am | RNS | Faridoxorubicin Program Clinical Updates |
| 21st Jan 2026 7:00 am | RNS | FDA Clearance of IND Application for AVA6103 |
| 20th Jan 2026 7:01 am | RNS | Year-end trading update |